Agilent companion diagnostic expands ce-ivd mark for pd-l1 ihc 28-8 pharmdx to include esophageal squamous cell carcinoma

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced it has expanded ce-ivd marking in the european union for its pd-l1 ihc 28-8 pharmdx as an aid in identifying esophageal squamous cell carcinoma patients for treatment with bristol myers squibb's pd-1-targeted immunotherapeutic opdivo® (nivolumab), in combination with fluoropyrimidine and platinum-based chemotherapy or opdivo® in combination with yervoy® (ipilimumab). these combined treatments provide new h
A Ratings Summary
A Quant Ranking